Literature DB >> 23235299

Characterization of sociodemographic and clinicopathological features in Brazilian patients with vulvar squamous cell carcinoma.

Beatriz de Melo Maia1, Flávia Munhoz Cestari, André Mourão Lavorato-Rocha, Iara Sant'Ana Rodrigues, Glauco Baiocchi, Gustavo Cardoso Guimarães, José Vassallo, Mônica Stiepcich, Fernando Augusto Soares, Rafael Malagoli Rocha.   

Abstract

AIM: To investigate sociodemographic and clinical-epidemiological profiles of patients with vulvar carcinoma in São Paulo, the largest city of Brazil, to establish a more consistent profile of these features once the incidence of vulvar carcinoma has risen considerably. Data regarding the epidemiological aspects of this tumor are scarce.
METHODS: A retrospective study was performed using 300 medical records from patients diagnosed with squamous cell carcinoma of the vulva and surgically treated at A.C. Camargo Hospital in São Paulo, Brazil, from 1978 to 2009.
RESULTS: The median age of onset was 70 years, ranging from 15 to 98 years, and most women were white (88.51%). Most patients (83.54%) had little or no schooling and had the lowest survival curve. Many patients were diagnosed in the early stages of the disease (57.09% FIGO IB), 59% had complications due to surgery and 43.71% had disease recurrence, of which about 70% died.
CONCLUSIONS: Our study adds 300 Brazilian cases of vulvar carcinoma to the world literature. Given the high rate of disease recurrence and mortality in Brazil, we conclude that regular gynecologic evaluation and educational policies should be reinforced in order to raise awareness for vulvar cancer.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 23235299     DOI: 10.1159/000343758

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  7 in total

1.  Cell cycle suppressor proteins are not related to HPV status or clinical outcome in patients with vulvar carcinoma.

Authors:  André Mourão Lavorato-Rocha; Iara Sant'ana Rodrigues; Beatriz de Melo Maia; Mônica Maria Ágata Stiepcich; Glauco Baiocchi; Kátia Cândido Carvalho; Fernando Augusto Soares; José Vassallo; Rafael Malagoli Rocha
Journal:  Tumour Biol       Date:  2013-07-06

2.  Epithelial-mesenchymal transition (EMT) in vulvar cancer with and without inguinal lymph node involvement.

Authors:  Christine E Brambs; Lars-Christian Horn; Meinhard Mende; Michael Höckel; Christine Eckey; Gesine Grit Ruth Hiller; Anne Kathrin Höhn
Journal:  J Cancer Res Clin Oncol       Date:  2021-09-08       Impact factor: 4.322

3.  A Thirty-year Review of Vulvar Cancer in Jamaica, 1978 to 2007.

Authors:  M E Bromfield; T N Gibson; B Hanchard; N Waugh; D McNaughton
Journal:  West Indian Med J       Date:  2014-04-11       Impact factor: 0.171

4.  ROCK1 as a novel prognostic marker in vulvar cancer.

Authors:  Erica M Akagi; André M Lavorato-Rocha; Beatriz de Melo Maia; Iara S Rodrigues; Kátia C Carvalho; Monica M Stiepcich; Glauco Baiocchi; Yukie Sato-Kuwabara; Silvia R Rogatto; Fernando A Soares; Rafael M Rocha
Journal:  BMC Cancer       Date:  2014-11-07       Impact factor: 4.430

5.  MiR-223-5p works as an oncomiR in vulvar carcinoma by TP63 suppression.

Authors:  Beatriz de Melo Maia; Iara Santana Rodrigues; Erica Mie Akagi; Nayra Soares do Amaral; Hui Ling; Paloma Monroig; Fernando Augusto Soares; George Adrian Calin; Rafael Malagoli Rocha
Journal:  Oncotarget       Date:  2016-08-02

6.  Assessment of TSPAN Expression Profile and Their Role in the VSCC Prognosis.

Authors:  Kelly Pedrozo Ferreira; Bruna Cristine de Almeida; Laura Gonzalez Dos Anjos; Glauco Baiocchi; Fernando Augusto Soares; Rafael Malagoli Rocha; Edmund Chada Baracat; Andrey Senos Dobroff; Katia Candido Carvalho
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923

7.  Epithelial-mesenchymal transition-like events in vulvar cancer and its relation with HPV.

Authors:  I S Rodrigues; A M Lavorato-Rocha; B de M Maia; M M A Stiepcich; F M de Carvalho; G Baiocchi; F A Soares; R M Rocha
Journal:  Br J Cancer       Date:  2013-06-18       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.